Vir Biotechnology Announces New Clinical Data From its Broad Hepatitis B Program

– Results from ongoing trials of VIR-2218 and VIR-3434 presented at the International Liver Congress(TM) (ILC) 2022 demonstrate durable reductions in hepatitis B surface antigen with no safety signals –

The post Vir Biotechnology Announces New Clinical Data From its Broad Hepatitis B Program appeared first on Bio Tech Winners.

Read MoreBio Tech Winners